Fib to Alb Ratio in Type 2 Dkd

Launched by ASSIUT UNIVERSITY · Jan 11, 2023

Keywords

ClinConnect Summary

This clinical trial, titled "Fib to Alb Ratio in Type 2 DKD," is looking to understand how the ratio of fibrinogen to albumin (two proteins in the blood) is related to diabetic kidney disease (DKD) in people with type 2 diabetes. The goal is to see if this ratio can help predict and possibly prevent the worsening of kidney problems in these patients. The study will not begin recruiting participants just yet, but it aims to include adults over 18 years old, specifically 50 individuals with type 2 diabetes who have DKD (indicated by certain signs in their urine and eye health) and 50 who do not have DKD.

If you meet the eligibility criteria, you could be part of this important research. Participants can expect to contribute to our understanding of how diabetes affects kidney health and may help develop ways to better manage this condition. However, people under 18, those with severe kidney disease, certain heart issues, active infections, or specific other health problems will not be able to join. Your participation could play a significant role in advancing knowledge and treatment for individuals with type 2 diabetes and kidney disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age above 18 yrs.
• • 50 Pts with type 2 DM that have DKD (presence of albuminuria in association with diabetic retinopathy) and 50 pts with type 2 DM but have no DKD.
• Exclusion Criteria:
• • Age below 18 yrs.
• • Pts with ESKD, manifested cardiac valvular disease, acute infection, history of hepatitis, pts with DKA and Cancer.
• • Pt who refused to contribute in this study